This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Zydus launches biosimilar for ophthalmic care

Zydus Lifesciences has introduced Anyra, its first indigenously developed biosimilar for the treatment of visual impairment in India. This innovative drug, akin to Aflibercept 2 mg, addresses vision loss resulting from diseases like diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eCiGEwj
via IFTTT

Pharma firms asked for side-effects of common medicines

India's drug regulator has issued new safety warnings for common medicines. Doxycycline, an antibiotic, will now list side effects like anxiety and dizziness. Carbimazole, used for thyroid issues, will highlight the risk of a life-threatening condition called agranulocytosis. Manufacturers must update package inserts and promotional materials. These changes follow recommendations from pharmacovigilance experts to ensure patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QCPknbg
via IFTTT

Warburg Pincus talks in final lap to buy Integrace Health for Rs 1,200 crore

Integrace is currently owned by homegrown PE fund True North and Singapore sovereign investor Temasek Holdings. True North Fund VI LLP holds a 55.83% stake in Integrace, while Temasek arm V-Science Investments Pte owns 43.91%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t7hfmGZ
via IFTTT

Steroid abuse among gym-goers raises heart, liver risks; issue raised in Parliament

Young people are facing severe health issues due to steroids and unsafe supplements. Doctors report liver toxicity, infertility, and aggression. Heart specialists warn of life-threatening consequences like heart attacks. Mental health experts note links to depression and anxiety. The market for these substances requires stricter checks and greater awareness among youth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HaBfwyV
via IFTTT

Seeing with sound: AIIMS distributes AI-powered smart glasses to help visually impaired

AIIMS has equipped 53 visually impaired individuals with advanced AI-powered smart vision glasses, transforming their environments into audible guidance. This innovative project empowers both children and adults to navigate life with newfound independence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yZ6uDUx
via IFTTT

AI can address health inequities, but cannot replace human touch: Union MoS Health Anupriya Patel

Speaking at the AI Impact Summit in the national capital, Patel asserted that India's governance model positions AI as an enabler and force multiplier, bringing the country closer to the goals of inclusivity and health equity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wjVESA
via IFTTT

29 vitamin-mineral FDC drugs under review for possible ban over 'irrational' tag

A looming ban on twenty-nine vitamin and mineral combination drugs has sparked a heated debate. Initially flagged as irrational by an expert panel in 2015, these products are now being re-evaluated by a specialized sub-committee. Before any final ruling, the companies will be given a chance to defend their products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eWhaIyb
via IFTTT